2003
DOI: 10.1016/j.ajkd.2003.07.008
|View full text |Cite
|
Sign up to set email alerts
|

Thrombotic microangiopathy after renal transplantation in the United States1 1The opinions expressed are solely those of the authors and do not represent an endorsement by the Department of Defense or the National Institutes of Health.This is a US government work. There are no restrictions on its use.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

6
53
1
1

Year Published

2009
2009
2017
2017

Publication Types

Select...
4
3
2

Relationship

0
9

Authors

Journals

citations
Cited by 193 publications
(61 citation statements)
references
References 38 publications
6
53
1
1
Order By: Relevance
“…De novo TMA after kidney transplantation is far less common with a reported incidence of only 0.8% in the analysis of United States Renal Data Systems [10]. Typically, it develops in the early posttransplant period; however, it may also be recognized years after transplant [11].…”
Section: Discussionmentioning
confidence: 99%
“…De novo TMA after kidney transplantation is far less common with a reported incidence of only 0.8% in the analysis of United States Renal Data Systems [10]. Typically, it develops in the early posttransplant period; however, it may also be recognized years after transplant [11].…”
Section: Discussionmentioning
confidence: 99%
“…De novo TMA is much less common than recurrent HUS. [5] In view of the distinct characteristics and clinical courses, it has been suggested to classify posttransplant TMA into localized and systemic forms. Systemic form is TMA associated with thrombocytopenia and microangiopathic hemolysis.…”
Section: Discussionmentioning
confidence: 99%
“…The incidence of de novo TMA posttransplant has been reported as 0.8–3.3% (36, 37). Drug-induced TMA has been associated with both CNIs (38, 39) and with mTOR inhibitors (40).…”
Section: Aims and Methodsmentioning
confidence: 99%
“…Conventional therapies such as withdrawal of the offending drug (usually CNI), switching drugs, and plasma exchange have resulted in poor graft outcomes. Drug withdrawal has been associated with a 50% graft survival rate at 3 years (36). Plasma exchange has been associated with an immediate graft loss rate of 20% and 1-year graft survival of only 66% (41).…”
Section: Aims and Methodsmentioning
confidence: 99%